TargetMol

Nilofabicin

Product Code:
 
TAR-T19642
Product Group:
 
Inhibitors and Activators
Supplier:
 
TargetMol
Regulatory Status:
 
RUO
Shipping:
 
cool pack
Storage:
 
-20℃
1 / 1
❮❯

No additional charges, what you see is what you pay! *

CodeSizePrice
TAR-T19642-5mg5mg£115.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T19642-1mL1 mL * 10 mM (in DMSO)£122.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T19642-10mg10mg£135.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T19642-25mg25mg£177.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T19642-50mg50mg£229.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T19642-100mg100mg£334.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
Prices exclude any Taxes / VAT
How to order with us   Contact us
Stay in control of your spending. These prices have no additional charges, not even shipping!
* Rare exceptions are clearly labelled (only 0.14% of items!).
Multibuy discounts available! Contact us to find what you can save.
This product comes from: United States.
Typical lead time: 10-14 working days.
Contact us for more accurate information.
  • Further Information
  • Documents
  • References
  • Show All

Further Information

Bioactivity:
Nilofabicin is a potent inhibitor of enoyl-(acyl-carrier-protein) reductase fall(FabI) and can be used in studies about the treatment of complicated acute.
CAS:
934628-27-0
Formula:
C19H20N2O2S
Molecular Weight:
340.44
Pathway:
Microbiology/Virology
Purity:
0.98
SMILES:
Cc1c(N)cccc1Cn1ccc(OCCc2cccs2)cc1=O
Target:
Antibacterial

References

1. Kim BY, Sohn YT. Solid state of CG-400549, a novel FabI inhibitor: characterization, dissolution, transformation. Arch Pharm Res. 2011 May;34(5):775-9. doi: 10.1007/s12272-011-0511-7. Epub 2011 Jun 9. PubMed PMID: 21656363. 2. Bogdanovich T, Clark C, Kosowska-Shick K, Dewasse B, McGhee P, Appelbaum PC. Antistaphylococcal activity of CG400549, a new experimental FabI inhibitor, compared with that of other agents. Antimicrob Agents Chemother. 2007 Nov;51(11):4191-5. Epub 2007 Sep 17. PubMed PMID: 17875997; PubMed Central PMCID: PMC2151435. 3. Yum JH, Kim CK, Yong D, Lee K, Chong Y, Kim CM, Kim JM, Ro S, Cho JM. In vitro activities of CG400549, a novel FabI inhibitor, against recently isolated clinical staphylococcal strains in Korea. Antimicrob Agents Chemother. 2007 Jul;51(7):2591-3. Epub 2007 Apr 9. PubMed PMID: 17420210; PubMed Central PMCID: PMC1913239.